Preorganization of the hydroxyethylene dipeptide isostere: The preferred conformation in solution resembles the conformation bound to BACE

Journal of Medicinal Chemistry

Volumn 48, Issue 24, 2005, Pages 7623-7627

  Vidal, Paloma ^a   Timm, David ^b   Broughton, Howard ^a   Chen, Shu Hui ^b   Martín, José A ^a   Rivera Sagredo, Alfonso ^a   McCarthy, James R ^b   Shapiro, Michael J ^b   Espinosa, Juan F ^a  

^a ELI LILLY AND COMPANY   (Spain)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; BETA SECRETASE; BETA SECRETASE INHIBITOR; HYDROXYETHYLENE DIPEPTIDE ISOSTERE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL BOND; DRUG BINDING; DRUG CONFORMATION; DRUG STRUCTURE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ANALYSIS;

AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ENDOPEPTIDASES; CRYSTALLOGRAPHY, X-RAY; DIPEPTIDES; ENDOPEPTIDASES; HUMANS; LEUCINE; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHENYLALANINE; PROTEASE INHIBITORS; SOLUTIONS; VALINE;

EID: 28144436378     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050631+     Document Type: Article

References (30)

1. Cooper, J. B. Aspartic Proteinases in Disease: a Structural Perspective. Curr. Drug Targets 2002, 3, 155-173.
2. Hyland, L. J.; Tomaszek, T. A., Jr.; Meek, T. D. Human Immunodeficiency Virus-1 Protease. 2. Use of pH Rate Studies and Solvent Kinetic Isotope Effects to Elucidate Details of Chemical Mechanism. Biochemistry 1991, 30, 8454-8463.
3. Rich, D. H. Peptidase Inhibitors. In Comprehensive Medicinal Chemistry. The Rational Design, Mechanistic Study and Therapeutic Application of Chemical Compounds; Hansh, C., Sammes, P. G., Taylor, J. B., Eds.; Pergamon Press: 1990; pp 391-441.
4. Szelke, M. Chemistry of Renin Inhibitors. In Aspartic Proteinases and their Inhibitors; Kostka, V., Eds.; de Gruyter: Berlin, Germany, 1985; pp 421-441.
5. Lebon, F.; Ledecq, M. Approaches to the Design of Effective HIV-1 Protease Inhibitors. Curr. Med. Chem. 2000, 7, 455-477.
6. Horn, R. K.; Gailunas, A. F.; Mamo, S.; Fang, L. Y.; Tung, J. S.; Walker, D. E.; Davis, D.; Thorsett, E. D.; Jewett, N. E.; Moon, J. B.; John, V. Design and Synthesis of Hydroxyethylene-Based Peptidomimetic Inhibitors of Human β-Secretase. J. Med. Chem. 2004, 47, 158-164.
7. Fairlie, D. P.; Tyndall, J. D. A.; Reid, R. C.; Wong, A. K.; Abbenante, G.; Scanlon, M. J.; March, D. R.; Bergman, D. A.; Chai, C. L. L.; Burkett, B. A. Conformational Selection of Inhibitors and Substrates by Proteolytic Enzymes: Implications for Drug Design and Polypeptide Processing. J. Med. Chem. 2000, 43, 1271-1281.
8. Tyndall, J. D. A.; Nall, T.; Fairlie, D. P. Proteases Universally Recognize Beta Strands in Their Active Sites. Chem. Rev. 2005, 105, 973-999.
9. Loughlin, W. A.; Tyndall, J. D. A.; Glenn, M. P.; Fairlie, D. P. Beta-Strand Mimetics. Chem. Rev. 2004, 104, 6085-6117.
10. Hoffmann, R. W. Flexible Molecules with Defined Shape-Conformational Design. Angew. Chem., Int. Ed. Engl. 1992, 31, 1124-1134.
11. Hoffmann, R. W. Conformational Design of Open-Chain Compounds. Angew. Chem., Int. Ed. 2000, 39, 2054-2070.
12. Sukopp, M.; Marinelli, L.; Heller, M.; Brandi, T.; Goodman, S. L.; Hoffman, R. W.; Kessler, H. Designed Beta-Turn Mimic Based on the Allylic-Strain Concept: Evaluation of Structural and Biological Features by Incorporation into Cyclic RGD Peptide (Cyclo(-L-arginylglycyl-L-α-aspartyl-)). Helv. Chim. Acta 2002, 85, 4442-4452.
13. Chen, S.-H.; Lamar, J.; Guo, D.; Kohn, T.; Yang, H.-C.; McGee, J.; Timm, D.; Erickson, J.; Yip, Y.; May, P.; McCarthy, J. P3 Cap Modified Phe*-Ala Series BACE Inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 245-250.
14. John, V.; Beck, J. P.; Bienkowski, M. J.; Sinha, S.; Heinrikson, R. L. Human β-Secretase (BACE) and BACE Inhibitors. J. Med. Chem. 2003, 46, 4625-4630.
15. Tung, J. S.; Davis, D. L.; Anderson, J. P.; Walker, D. E.; Shumeye, M.; Jewett, N.; Horn, R. K.; Sinha, S.; Thorsett, E. D.; John, V. Design of Substrate-Based Inhibitors of Human β-Secretase. J. Med. Chem. 2002, 45, 259-262.
16. Haasnot, C. A. G.; de Leeuw, F. A. A. M.; Altona C. The Relationship between Proton-Proton NMR Coupling Constants and Substituent Electronegativities-I. Tetrahedron 1980, 36, 2783-2792.
17. Kessler, H.; Konat, R. K.; Schmitt, W. Conformational Analysis of Peptides: Application to Drug Design. In NMR in Drug Design; Craik, D. J., Eds.; CRC Press: Boca Raton, FL, 1996; pp 215-244.
18. Halgren, T. A. Merck Molecular Force Field. I. Basis, Form, Scope, Parametrization, and Performance of MMFF94. J. Comput. Chem. 1996, 17, 490-519.
19. Goudreau, N.; Cameron, D. R.; Bonneau, P.; Gorys, V.; Plouffe, C.; Poirier, M.; Lamarre, D.; Llinas-Brunet, M. NMR Structural Characterization of Peptide Inhibitors Bound to the Hepatitis C Virus NS3 Protease: Design of a New P2 Substituent. J. Med. Chem. 2004, 47, 123-132.
20. Wüthrich, K. NMR of Proteins and Nucleic Acids; Wiley: New York, 1986.
21. Smith, L. J.; Bolin K. A.; Schwalbe, H.; MacArthur, M. W.; Thornton, J. M.; Dobson, C. M. Analysis of Main Chain Torsion Angles in Proteins: Prediction of NMR Coupling Constants for Native and Random Coil Conformations. J. Mol. Biol. 1996, 255, 494-506.
22. Fiebig, K. M.; Schwalbe, H.; Buck, M.; Smith, L. J.; Dobson, C. M. Toward a Description of the Conformations of Denatured States of Proteins. Comparison of a Random Coil Model with NMR Measurements. J. Phys. Chem. 1996, 100, 2661-2666.
23. Glenn, M. P.; Fairlie, D. P. Mimetics of the Peptide β-Strand. Mini Rev. Med. Chem. 2002, 2, 433-445.
24. Tyndall, J. D. A.; Fairlie, D. P. Macrocycles Mimic the Extended Peptide Conformation Recognized By Aspartic, Serine, Cysteine and Metallo Proteases. Curr. Med. Chem. 2001, 8, 893-907.
25. Burns, C. J.; Guitton, J.-D.; Baudoin, B.; Lelievre, Y.; Duchesne, M.; Parker, F.; Fromage, N.; Commercon, A. Novel Conformationally Extended Naphthalene-Based Inhibitors of Farnesyltransferase. J. Med. Chem. 1997, 40, 1763-1767.
26. Ro, S.; Baek, S.-G.; Lee, B.; Park, C.; Choy, N.; Sun Lee, C.; Chan Son, Y.; Choi, H.; Sung Koh, J.; Yoon, H.; Chun Kim, S.; Hoa Ok, J. NMR and Topochemical Studies of Peptidomimetic HIV-I Protease Inhibitors Containing a cis-Epoxide Amide Isostere. Bioorg. Med. Chem. Lett. 1998, 8, 2423-2426.
27. Smith, A. B., III; Hirschmann, R.; Pasternak, A.; Yao, W.; Sprengeler, P. A.; Holloway, M. K.; Kuo, L. C.; Chen, Z.; Darke, P. L.; Schleif, W. A. An Orally Bioavailable Pyrrolinone Inhibitor of HIV-1 Protease: Computational Analysis and X-ray Crystal Structure of the Enzyme Complex. J. Med. Chem. 1997, 40, 2440-2444.
28. Nadin, A.; Derrer, S.; McGeary, R. P.; Goodman, J. M.; Raithby, P. R.; Holmes, A. B.; O'Hanlon, P. J.; Pearson, N. D. Seven-Membered Lactams as Constraints for Amide Self-Recognition. J. Am. Chem. Soc. 1995, 117, 9768-9769.
29. Veale, C. A.; Bernstein, P. R.; Bryant, C.; Ceccarelli, C.; Damewood, J. R., Jr.; Earley, R.; Feeney, S. W.; Gomes, B.; Kosmider, B. J.; Steelman, G. B.; Thomas, R. M.; Vacek, E. P.; Williams, J. C.; Wolanin, D. J.; Woolson, S. Nonpeptidic Inhibitors of Human Leukocyte Elastase. 5. Design, Synthesis, and X-ray Crystallography of a Series of Orally Active 5-Aminopyrimidin-6-one- Containing Trifluoromethyl Ketones. J. Med. Chem. 1995, 38, 98-108.
30. Hanessian, S.; Brassard, M. Stereoselective Synthesis of Constrained Oxacyclic Hydroxyethylene Isosteres of Aspartyl Protease Inhibitors. Nitroaldol Methodology toward 2,3-Substituted Tetrahydrofurans. Tetrahedron 2004, 60, 7621-7628.